Boston Scientific Corporation vs DexCom, Inc. — how do they compare? Boston Scientific Corporation trades at $51.17 (market cap $74.19B), while DexCom, Inc. trades at $89.2 (market cap $33.79B). The key difference: Boston Scientific Corporation is far larger — about 2.2× DexCom, Inc.'s market cap, and DexCom, Inc. is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | DXCM | |
|---|---|---|
Market Cap | $74.19B | $33.79B |
Sector | Health | Health |
52-Week High | $108.14 | $89.53 |
52-Week Low | $42.63 | $54.84 |
Enterprise Value | $86.27B | $33.24B |
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →